- Home
- REE vs QTTB Comparison
REE vs QTTB Comparison
Compare REE & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- QTTB
- Stock Information
- Founded
- REE 2011
- QTTB 2015
- Country
- REE Israel
- QTTB United States
- Employees
- REE N/A
- QTTB N/A
- Industry
- REE Auto Manufacturing
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- QTTB Health Care
- Exchange
- REE Nasdaq
- QTTB Nasdaq
- Market Cap
- REE 22.4M
- QTTB 23.3M
- IPO Year
- REE N/A
- QTTB N/A
- Fundamental
- Price
- REE $1.21
- QTTB $2.95
- Analyst Decision
- REE Strong Buy
- QTTB Hold
- Analyst Count
- REE 2
- QTTB 7
- Target Price
- REE $11.75
- QTTB $12.17
- AVG Volume (30 Days)
- REE 1.1M
- QTTB 542.6K
- Earning Date
- REE 12-19-2025
- QTTB 11-07-2025
- Dividend Yield
- REE N/A
- QTTB N/A
- EPS Growth
- REE N/A
- QTTB N/A
- EPS
- REE N/A
- QTTB N/A
- Revenue
- REE $183,000.00
- QTTB N/A
- Revenue This Year
- REE $327.73
- QTTB N/A
- Revenue Next Year
- REE $36,888.82
- QTTB N/A
- P/E Ratio
- REE N/A
- QTTB N/A
- Revenue Growth
- REE N/A
- QTTB N/A
- 52 Week Low
- REE $0.53
- QTTB $1.35
- 52 Week High
- REE $11.72
- QTTB $53.17
- Technical
- Relative Strength Index (RSI)
- REE 63.27
- QTTB 53.63
- Support Level
- REE $1.14
- QTTB $2.55
- Resistance Level
- REE $1.41
- QTTB $3.60
- Average True Range (ATR)
- REE 0.18
- QTTB 0.39
- MACD
- REE 0.02
- QTTB -0.08
- Stochastic Oscillator
- REE 42.82
- QTTB 42.10
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.